Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;51(8):e13603.
doi: 10.1111/eci.13603. Epub 2021 Jun 4.

Respiratory follow-up after hospitalization for COVID-19: Who and when?

Marianne Riou  1   2   3 , Christophe MarcoT  3 , Walid Oulehri  2   4 , Irina Enache  1   2 , Cristina Pistea  1 , Eva Chatron  3 , Aissam Labani  5 , Bernard Geny  1   2 , Mickael Ohana  5 , Frederic De Blay  2   3 , Romain Kessler  3   6 , Anne Charloux  1   2
Affiliations

Respiratory follow-up after hospitalization for COVID-19: Who and when?

Marianne Riou et al. Eur J Clin Invest. 2021 Aug.
No abstract available

Keywords: COVID-19; respiratory function; respiratory outcome; respiratory sequelae.

PubMed Disclaimer

Conflict of interest statement

All authors except Frédéric De Blay have no conflict of interest. Pr De Blay perceived financial supports from Aimmune, Stallergènes Greer, Mundipharma, Novartis, Regeneron, DVB, Sanofi, ALK, Boehringer and AstraZeneca, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Pulmonary function test (PFT) (diffusion capacity for carbon monoxide [DLCO] and total lung capacity [TLC]) and chest CT scan results of the 81 patients. As defined by the World Health Organization, patients with COVID‐19 were stratified in 3 groups: mild‐to‐moderate disease (n = 21), severe disease (n = 15) and critical disease (n = 45). Patients with abnormal CT scan or PFT at 3 months were re‐evaluated at 6 months. &: only 3 patients were re‐evaluated, precluding any conclusion about this group. Quantitative variables are presented as median and interquartile range, or number of patients (%). *P < .05, **P < .01 and ***P < .001: comparison between the groups of patients at 3 and 6 months. At 6 months, only 2 groups were compared (mild‐to‐moderate versus critical disease). A and B. Example of persistent lung opacities—mostly peripheral ground‐glass opacities—on chest CT performed at 3 (A) and 6 months (B) after critical COVID‐19, in a 60‐year‐old man. At 6 months, lung infiltrates diminished in extension and density with minimal signs of fibrosis
See this image and copyright information in PMC

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506. - PMC - PubMed
    1. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID‐19 patients at time of hospital discharge. Eur Respir J. 2020;55(6):2001217. - PMC - PubMed
    1. Chang Y‐C, Yu C‐J, Chang S‐C, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin‐section CT. Radiology. 2005;236(3):1067‐1075. - PubMed
    1. Ketai L, Paul NS, Wong KT. Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic‐radiologic correlates of an emerging disease. J Thorac Imaging. 2006;21(4):276‐283. - PubMed
    1. Ahmed H, Patel K, Greenwood DC, et al. Long‐term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta‐analysis. J Rehabil Med. 2020;52(5):jrm00063. - PubMed

MeSH terms